The Preclinical and Clinical Effects of Vilazodone for the Treatment ...

Vilazodone has shown efficacy versus placebo in improving depression symptoms in several double-blind, placebo-controlled trials.

Vilazodone was generally well tolerated, with the most common treatment-emergent adverse events being mild or moderate diarrhoea, nausea and ...

Vilazodone for the Treatment of Major Depressive Disorder

However, its potential advantage over other antidepressants could be speculated from its distinctive mechanism of action and clinical and pre- ...

The Preclinical and Clinical Effects of Vilazodone for the Treatment ...

The US Food and Drug Administration (FDA) approved the antidepressant drug vilazodone (EMD 68843), a novel SSRI and 5-HT1A receptor partial agonist. Vilazodone ...

Influence of CYP3A4 Induction/Inhibition on the Pharmacokinetics of ...

Vilazodone, a serotonin reuptake inhibitor and 5-HT1A partial agonist, is approved by the US Food and Drug Administration for the treatment of ...

Vilazodone for Major Depression in Adults: Pharmacological Profile ...

There was significant improvement in depressive symptoms in both treatment groups; however, no significant between-group differences were ...

Vilazodone for the Treatment of Depression - Wesley T Lindsey, 2011

Vilazodone is an antidepressant recently approved by the Food and Drug Administration (FDA) that is first in a new class regarding mechanism of action. It has ...

The antidepressant drug vilazodone is an allosteric inhibitor ... - Nature

Depression is a common mental disorder. The standard medical treatment is the selective serotonin reuptake inhibitors (SSRIs).

022567Orig1s000 - accessdata.fda.gov

The clinical development program of vilazodone for the treatment ... Randomized, Parallel Study to Define the ECG Effects of Vilazodone Using a ...

Clinical utility of vilazodone for the treatment of adults with major ...

Vilazodone was superior to placebo in the improvement of depressive symptoms, and evaluation of population subgroups based on age, gender, and race did not ...

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED ...

Vilazodone, a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist, is approved for treating major depressive disorder in ...

ACS Chemical Neuroscience Molecule Spotlight on Viibryd ...

(1) Thus, any new treatment that can improve upon these side effects would be beneficial to patients with MDD. ... The clinical efficacy of ...

Vilazodone - an overview | ScienceDirect Topics

Multiple clinical trials have shown that it is efficacious in treating MDD [28], which is the only current indication for use. Like vortioxetine, vilazodone may ...

Vilazodone - SEC.gov

We are planning clinical studies that will evaluate the safety and efficacy of vilazodone in treating depression. In these studies, we seek to determine the ...

Sexual dysfunction during treatment of major depressive...

Both vilazodone doses and citalopram were generally well tolerated. The effect of vilazodone on sexual functioning was prospectively measured by CSFQ mean score ...

Vilazodone for the Treatment of Depression: An Update. - Europe PMC

Vilazodone has been speculated to have three potential benefits including faster onset of action, greater efficacy, and better tolerability ...

A novel antidepressant or simply another SSRI? - ResearchGate

Introduction: Vilazodone is the newest serotonergic antidepressant to be approved by the FDA for the treatment of major depressive disorder (MDD).

Vilazodone: a brief pharmacological and clinical review of the novel ...

Vilazodone will lend itself to the current armamentarium in the treatment of major depressive disorder and may hold promise for patients who cannot tolerate ...

Vilazodone: a brief pharmacological and clinical review of the novel ...

Results: Randomized, controlled empirical data for vilazodone have gained it approval for treating major depressive disorder. It combines two well known ...

The clinical utility of newer antidepressant agents - Allen Press

Vilazodone's partial agonism of the presynaptic 5HT1A autoreceptors may enhance the serotonergic effect, and it was hypothesized that this would ...